• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President, Global Head of R&D Wang Lai sold $295,553 worth of American Depositary Shares (1,068 units at $276.74), closing all direct ownership in the company (SEC Form 4) (withholding tax)

    6/25/26 5:14:55 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wang Lai

    (Last)(First)(Middle)
    C/O BEONE MEDICINES I GMBH
    AESCHENGRABEN 27, 21ST FLOOR

    (Street)
    BASEL4051

    (City)(State)(Zip)

    SWITZERLAND

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    BeOne Medicines Ltd. [ ONC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    President, Global Head of R&D
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/23/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Ordinary Shares1,681,004D
    Ordinary Shares601,965ISee Footnote(1)
    RMB Shares(2)0(3)(4)ISee Footnote(4)
    American Depositary Shares(5)06/23/2026S(6)1,068D$276.7350D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
    2. The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
    3. The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
    4. The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
    5. Each American Depositary Share represents 13 Ordinary Shares.
    6. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
    Remarks:
    /s/ Qing Nian, as Attorney-in-Fact06/25/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ONC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    7/13/2026$380.00Hold → Buy
    Jefferies
    3/27/2026$340.00Outperform
    Wolfe Research
    3/16/2026$290.00Buy → Hold
    Jefferies
    11/24/2025Buy
    Truist
    9/18/2025$385.00Overweight
    Barclays
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    SEC Filings

    View All

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    7/14/26 4:48:02 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    7/10/26 4:36:01 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    7/10/26 4:35:18 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Oyler John sold $34,590,855 worth of American Depositary Shares (109,713 units at $315.28) as part of a pre-agreed trading plan and exercised 33,990 units of American Depositary Shares at a strike of $119.96, closing all direct ownership in the company (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    7/22/26 5:03:12 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Oyler John sold $20,163,907 worth of American Depositary Shares (64,628 units at $312.00) as part of a pre-agreed trading plan and exercised 64,628 units of American Depositary Shares at a strike of $119.96 (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    7/17/26 5:36:12 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Oyler John exercised 283,154 units of American Depositary Shares at a strike of $145.28 and sold $89,351,598 worth of American Depositary Shares (283,154 units at $315.56) as part of a pre-agreed trading plan (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    7/17/26 5:31:04 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BeOne Medicines upgraded by Jefferies with a new price target

    Jefferies upgraded BeOne Medicines from Hold to Buy and set a new price target of $380.00

    7/13/26 8:58:02 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on BeOne Medicines with a new price target

    Wolfe Research initiated coverage of BeOne Medicines with a rating of Outperform and set a new price target of $340.00

    3/27/26 8:46:31 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines downgraded by Jefferies with a new price target

    Jefferies downgraded BeOne Medicines from Buy to Hold and set a new price target of $290.00

    3/16/26 8:35:18 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

    BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global

    7/17/26 6:01:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

    Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-30

    6/30/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

    Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (

    6/12/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Financials

    Live finance-specific insights

    View All

    BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

    Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: "These strong first-quarter results reinforce BeOne's conti

    5/6/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

    Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announ

    2/26/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

    Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,

    11/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)